EGFR and non-small cell lung carcinoma: ,3 In 2017, osimertinib, a third-generation TKI, was approved by the Food and Drug Administration and European Medicines Agency as second line4 and more recently as first line for the treatment of metastatic EGFR-mutated NSCLC, which further improved survival.